Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Syndax Pharmaceuticals Inc. (SNDX:NASDAQ), powered by AI.
Syndax Pharmaceuticals Inc. is currently trading at $18.55. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Syndax Pharmaceuticals Inc. on Alpha Lenz.
Syndax Pharmaceuticals Inc.'s P/E ratio is -5.6.
“Syndax Pharmaceuticals Inc. trades at a P/E of -5.6 (undervalued) with modest ROE of -161.8%.”
Ask for details →Syndax Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies for cancer treatment. The primary mission of Syndax is to enhance and extend the lives of patients by significantly improving the efficacy of cancer therapies. Notably, the company is developing a pipeline of investigational drugs that aim to boost the immune system's ability to fight cancer and target the underlying genetic causes of cancer growth and persistence. Syndax Pharmaceuticals is particularly involved in researching epigenetic therapies and immuno-oncology, paving the way for new treatment paradigms. The company's contributions affect both the pharmaceutical industry and the wider healthcare sector by potentially offering new, effective therapeutic options for oncologists and their patients. As such, Syndax plays a vital role in the growing field of cancer therapeutics and continues to explore partnerships and collaborations to advance its groundbreaking research and development efforts.
“Syndax Pharmaceuticals Inc. trades at a P/E of -5.6 (undervalued) with modest ROE of -161.8%.”
Ask for details →Syndax Pharmaceuticals Inc. (ticker: SNDX) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 270 employees. Market cap is $1.6B.
The current price is $18.55 with a P/E ratio of -5.63x and P/B of 24.86x.
ROE is -161.82% and operating margin is -158.45%. Annual revenue is $172M.